Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pharming Group N.V. (PHARM.AS)
Leiden, NL
Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, Europe, and other international markets, focus on addressing rare diseases and critical unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor prescribed for managing acute attacks of hereditary angioedema. Pharming's development pipeline also encompasses rhC1INH, which is under investigation for potential applications in pre-eclampsia, acute kidney injury, and COVID-19. Furthermore, they are progressing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, for individuals afflicted with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases. The company maintains significant partnerships, including a development and license agreement with Novartis and a strategic alliance with Orchard Therapeutics plc. This latter collaboration involves the research, development, manufacture, and commercialization of OTL-105, an experimental ex-vivo autologous hematopoietic stem cell gene therapy designed to treat hereditary angioedema.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.81% | -14.66% | -23.76% | -13.38% | -22.34% | -21.26% | +29.05% | +3.78% | +3.68% | +435.12% | -98.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+36.5% ★ Q1'26: -9.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+126.6% ★ Q1'26: +68.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+4.2% Q1'26: +1.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+5.1% ★ Q1'26: -7.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+5.7% ★ Q1'26: -9.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.7% Q1'26: +11.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.64× ★ Q1'26: -13.58× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.84M
est: 12.40M (-4.5%)
|
16.69M
est: 13.54M (+23.3%)
|
107.52M
est: 96.72M (+11.2%)
|
154.58M
est: 161.80M (-4.5%)
|
189.33M
est: 190.77M (-0.8%)
|
228.39M
est: 221.43M (+3.1%)
|
189.85M
est: 223.00M (-14.9%)
|
205.62M
est: 213.38M (-3.6%)
|
245.32M
est: 298.44M (-17.8%)
|
286.89M
est: 286.47M (+0.1%)
|
391.47M
est: 387.80M (+0.9%)
|
383.86M
371.09M – 392.78M
-1.0% YoY
|
387.87M
359.98M – 460.11M
+1.0% YoY
|
380.35M
359.96M – 421.79M
-1.9% YoY
|
447.20M
423.23M – 495.93M
+17.6% YoY
|
688.18M
651.30M – 763.17M
+53.9% YoY
|
| EBITDA |
-14.75M
est: 2.26M (-754.0%)
|
-13.88M
est: 2.46M (-663.2%)
|
-39.81M
est: 17.59M (-326.3%)
|
50.98M
est: 29.43M (+73.2%)
|
71.46M
est: 34.70M (+105.9%)
|
92.11M
est: 40.28M (+128.7%)
|
48.78M
est: 40.57M (+20.2%)
|
33.53M
est: 38.81M (-13.6%)
|
9.88M
est: 35.06M (-71.8%)
|
13.18M
est: 33.65M (-60.8%)
|
31.77M
est: 45.56M (-30.3%)
|
45.09M
43.59M – 46.14M
-1.0% YoY
|
45.57M
42.29M – 54.05M
+1.0% YoY
|
44.68M
42.29M – 49.55M
-1.9% YoY
|
52.53M
49.72M – 58.26M
+17.6% YoY
|
80.84M
76.51M – 89.65M
+53.9% YoY
|
| EBIT |
-9.90M
est: 1.50M (-760.1%)
|
-14.67M
est: 1.64M (-995.0%)
|
-80.43M
est: 11.71M (-787.0%)
|
17.35M
est: 19.58M (-11.4%)
|
65.66M
est: 23.09M (+184.3%)
|
50.04M
est: 26.80M (+86.7%)
|
29.17M
est: 26.99M (+8.1%)
|
20.35M
est: 25.83M (-21.2%)
|
-6.05M
est: 17.29M (-135.0%)
|
2.97M
est: 16.59M (-82.1%)
|
20.10M
est: 22.46M (-10.5%)
|
22.24M
21.50M – 22.75M
-1.0% YoY
|
22.47M
20.85M – 26.65M
+1.0% YoY
|
22.03M
20.85M – 24.43M
-1.9% YoY
|
25.90M
24.52M – 28.73M
+17.6% YoY
|
39.86M
37.73M – 44.21M
+53.9% YoY
|
| Net Income |
-10.89M
est: -17.53M (+37.9%)
|
-18.44M
est: -29.90M (+38.3%)
|
-95.92M
est: -58.22M (-64.8%)
|
28.59M
est: 26.17M (+9.3%)
|
40.54M
est: 40.78M (-0.6%)
|
37.75M
est: 53.05M (-28.8%)
|
16.00M
est: 26.58M (-39.8%)
|
13.67M
est: 33.56M (-59.3%)
|
-10.55M
est: -16.12M (+34.6%)
|
-10.64M
est: -9.61M (-10.8%)
|
2.97M
est: 2.30M (+29.0%)
|
12.24M
3.98M – 20.51M
+432.4% YoY
|
13.84M
-3.82M – 31.50M
+13.0% YoY
|
26.68M
23.96M – 29.40M
+92.8% YoY
|
31.18M
29.01M – 35.60M
+16.9% YoY
|
51.38M
47.80M – 58.66M
+64.8% YoY
|
| SGA |
5.28M
est: 5.83M (-9.5%)
|
8.07M
est: 6.37M (+26.7%)
|
44.86M
est: 45.52M (-1.4%)
|
53.49M
est: 76.15M (-29.8%)
|
65.90M
est: 89.78M (-26.6%)
|
69.97M
est: 104.21M (-32.9%)
|
92.05M
est: 104.95M (-12.3%)
|
131.82M
est: 100.42M (+31.3%)
|
87.50M
est: 155.64M (-43.8%)
|
161.84M
est: 149.40M (+8.3%)
|
219.55M
est: 202.24M (+8.6%)
|
200.19M
193.53M – 204.84M
-1.0% YoY
|
202.28M
187.74M – 239.95M
+1.0% YoY
|
198.36M
187.73M – 219.97M
-1.9% YoY
|
233.22M
220.72M – 258.63M
+17.6% YoY
|
358.90M
339.67M – 398.01M
+53.9% YoY
|
| EPS |
-0.02
est: -0.03 (+15.1%)
|
-0.04
est: -0.04 (+18.9%)
|
-0.15
est: -0.08 (-81.8%)
|
0.04
est: 0.04 (-7.3%)
|
0.05
est: 0.06 (-12.1%)
|
0.05
est: 0.08 (-39.7%)
|
0.02
est: 0.04 (-48.1%)
|
0.02
est: 0.05 (-65.5%)
|
-0.01
est: -0.02 (+40.6%)
|
-0.02
est: -0.01 (-29.1%)
|
0.00
est: 0.00 (+33.3%)
|
0.02
0.01 – 0.03
+451.6% YoY
|
0.02
-0.01 – 0.04
+13.0% YoY
|
0.04
0.03 – 0.04
+86.1% YoY
|
0.04
0.04 – 0.05
+21.1% YoY
|
0.07
0.07 – 0.08
+64.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Netherlands ETF EWN | 0.30% | 1.55M | 0.50% |
| 2 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.18% | 1.27M | 0.40% |
| 3 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.17% | 1.24M | 0.33% |
| 4 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.16% | 1.67M | 0.58% |
| 5 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.11% | 1.24M | 0.40% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.09% | 293.6K | 0.23% |
| 7 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.09% | 293.6K | 0.23% |
| 8 | iShares MSCI Europe Small-Cap ETF IEUS | 0.06% | 111.1K | 0.41% |
| 9 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.06% | 2.00M | 0.30% |
| 10 | Dimensional - International Small Cap ETF DFIS | 0.03% | 1.63M | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fabrice Chouraqui | Chief Executive Officer & Executive Director | 2M | male |
| Anurag Relan | Chief Medical Officer | — | male |
| Ines Bernal | Chief People Officer | — | female |
| Kenneth Lynard EMBA | Chief Financial Officer | — | male |
| Leverne Marsh | Chief Commercial Officer | — | female |
| Magnus Hansson | Medical Director | — | — |
| Michael Levitan | Vice President of Investor Relations & Corporate Communications | — | male |
| Mireille Sanders | Chief Operations Officer | — | female |
| Ruud Van Outersterp | Chief Legal & Compliance Officer | — | male |
| Alexander Breidenbach | Chief Business Officer | — | — |
| Susanne Embleton | Investor Relations Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHARM.AS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
